Exclusive Summary

• 1) Already registered across EU27 and the US with patents/exclusivities long expired, enabling rapid distribution deals; 2) Stable inpatient demand driven by ~1.0–1.1B global GERD patients and millions of annual non-variceal UGIB hospitalizations; 3) Guideline-backed as first-line/standard IV PPI after endoscopic hemostasis and when oral therapy is not possible; 4) Despite multi-source competition, hospital substitution opportunities remain, and the 40 mg vial flexibly supports both routine IV dosing and 80 mg loading (two vials); 5) EU/US registrations signal strong quality/compliance, easing reliance/abridged approvals and delivering clear cost savings vs brand.